Market Downturn: Tech and Biotech Stocks Face Significant Declines

Font: Financial Modeling Prep  • May 29, 2026

• Ambarella (NASDAQ: AMBA) experienced a sharp decline due to lower-than-expected sales guidance, raising investor concerns in the semiconductor sector.
• Biopharmaceutical companies like OCS (NASDAQ: OCS) and Co-Diagnostics (NASDAQ: CODX) saw significant drops, influenced by management stock transactions and broader biodefense sector shifts.
• An inverse ETF, Daily Target 2X Short SMCI ETF (NASDAQ: SMCZ), declined, indicating strong performance in its underlying Super Micro Computer stock, while Akari Therapeutics (NASDAQ: AKTX) fell despite positive drug news, highlighting biotech stock volatility.

Today's market sees significant declines, particularly in technology stocks and biotechnology stocks. Semiconductor firm Ambarella (NASDAQ: AMBA) records a 21.41% drop, with its stock price settling at $72.18. This fall follows the company's second-quarter sales guidance, which was lower than what Wall Street analysts expected, causing concern among investors about future revenue and market performance.

Biopharmaceutical firms also face downturns. OCS (NASDAQ: OCS) drops 23.42% to $22.71 after announcing management stock transactions related to vested RSUs. RSUs are shares given to employees that can be sold after a certain time, which can increase selling pressure. Meanwhile, Co-Diagnostics (NASDAQ: CODX) decreases 23.77% to $8.53 amid biodefense sector shifts.

Akari Therapeutics (NASDAQ: AKTX) falls 25.49% to $16.43 despite positive news about its lead drug candidate, showing the high-risk nature of biotech stocks. The Daily Target 2X Short SMCI ETF (NASDAQ: SMCZ) also drops 23.46% to $6.23. This is an inverse ETF, designed to move in the opposite direction of a stock. Its decline means the underlying Super Micro Computer stock performed very well, reflecting diverse market trends.

In summary, today's market losers were driven by specific events. Poor financial guidance hurt Ambarella, while biotech firms faced volatility from insider transactions and sector uncertainty. The inverse ETF's loss highlights a strong gain in its underlying stock, showing how different factors impact equity market performance.